295 related articles for article (PubMed ID: 21994752)
1. Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?
Nasr R; El Hajj H; Kfoury Y; de Thé H; Hermine O; Bazarbachi A
Viruses; 2011 Jun; 3(6):750-69. PubMed ID: 21994752
[TBL] [Abstract][Full Text] [Related]
2. Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation.
Yuen CK; Chan CP; Fung SY; Wang PH; Wong WM; Tang HV; Yuen KS; Chan CP; Jin DY; Kok KH
J Virol; 2016 Apr; 90(8):3902-3912. PubMed ID: 26819312
[TBL] [Abstract][Full Text] [Related]
3. ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.
Dassouki Z; Sahin U; El Hajj H; Jollivet F; Kfoury Y; Lallemand-Breitenbach V; Hermine O; de Thé H; Bazarbachi A
Blood; 2015 Jan; 125(3):474-82. PubMed ID: 25395419
[TBL] [Abstract][Full Text] [Related]
4. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia.
El Hajj H; El-Sabban M; Hasegawa H; Zaatari G; Ablain J; Saab ST; Janin A; Mahfouz R; Nasr R; Kfoury Y; Nicot C; Hermine O; Hall W; de Thé H; Bazarbachi A
J Exp Med; 2010 Dec; 207(13):2785-92. PubMed ID: 21135137
[TBL] [Abstract][Full Text] [Related]
5. Adult T-cell leukemia-lymphoma as a viral disease: Subtypes based on viral aspects.
Nosaka K; Matsuoka M
Cancer Sci; 2021 May; 112(5):1688-1694. PubMed ID: 33630351
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Hermine O; Dombret H; Poupon J; Arnulf B; Lefrère F; Rousselot P; Damaj G; Delarue R; Fermand JP; Brouet JC; Degos L; Varet B; de Thé H; Bazarbachi A
Hematol J; 2004; 5(2):130-4. PubMed ID: 15048063
[TBL] [Abstract][Full Text] [Related]
7. Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives.
Bazarbachi A; Hermine O
Virus Res; 2001 Oct; 78(1-2):79-92. PubMed ID: 11520582
[TBL] [Abstract][Full Text] [Related]
8. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.
El-Sabban ME; Nasr R; Dbaibo G; Hermine O; Abboushi N; Quignon F; Ameisen JC; Bex F; de Thé H; Bazarbachi A
Blood; 2000 Oct; 96(8):2849-55. PubMed ID: 11023521
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
Kchour G; Tarhini M; Kooshyar MM; El Hajj H; Wattel E; Mahmoudi M; Hatoum H; Rahimi H; Maleki M; Rafatpanah H; Rezaee SA; Yazdi MT; Shirdel A; de Thé H; Hermine O; Farid R; Bazarbachi A
Blood; 2009 Jun; 113(26):6528-32. PubMed ID: 19411628
[TBL] [Abstract][Full Text] [Related]
10. Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells.
Kinpara S; Kijiyama M; Takamori A; Hasegawa A; Sasada A; Masuda T; Tanaka Y; Utsunomiya A; Kannagi M
Retrovirology; 2013 May; 10():52. PubMed ID: 23688327
[TBL] [Abstract][Full Text] [Related]
11. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells.
Nasr R; Rosenwald A; El-Sabban ME; Arnulf B; Zalloua P; Lepelletier Y; Bex F; Hermine O; Staudt L; de Thé H; Bazarbachi A
Blood; 2003 Jun; 101(11):4576-82. PubMed ID: 12560223
[TBL] [Abstract][Full Text] [Related]
12.
Hachiman M; Yoshimitsu M; Ezinne C; Kuroki A; Kozako T; Arima N
Oncol Lett; 2018 Jul; 16(1):1305-1311. PubMed ID: 30061950
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide (As
Marçais A; Cook L; Witkover A; Asnafi V; Avettand-Fenoel V; Delarue R; Cheminant M; Sibon D; Frenzel L; de Thé H; Bangham CRM; Bazarbachi A; Hermine O; Suarez F
Retrovirology; 2020 Mar; 17(1):5. PubMed ID: 32199462
[TBL] [Abstract][Full Text] [Related]
14. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran.
Kchour G; Makhoul NJ; Mahmoudi M; Kooshyar MM; Shirdel A; Rastin M; Rafatpanah H; Tarhini M; Zalloua PA; Hermine O; Farid R; Bazarbachi A
Leuk Lymphoma; 2007 Feb; 48(2):330-6. PubMed ID: 17325893
[TBL] [Abstract][Full Text] [Related]
15. Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.
Nasr R; Marçais A; Hermine O; Bazarbachi A
Methods Mol Biol; 2017; 1582():197-216. PubMed ID: 28357672
[TBL] [Abstract][Full Text] [Related]
16. Niclosamide, an anti-helminthic molecule, downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2 proteins in HTLV-1-transformed T lymphocytes.
Xiang D; Yuan Y; Chen L; Liu X; Belani C; Cheng H
Biochem Biophys Res Commun; 2015 Aug; 464(1):221-228. PubMed ID: 26116531
[TBL] [Abstract][Full Text] [Related]
17. HTLV-1 Tax and adult T-cell leukemia.
Giam CZ; Jeang KT
Front Biosci; 2007 Jan; 12():1496-507. PubMed ID: 17127397
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells.
Bazarbachi A; El-Sabban ME; Nasr R; Quignon F; Awaraji C; Kersual J; Dianoux L; Zermati Y; Haidar JH; Hermine O; de Thé H
Blood; 1999 Jan; 93(1):278-83. PubMed ID: 9864171
[TBL] [Abstract][Full Text] [Related]
19. Role of the HTLV-1 viral factors in the induction of apoptosis.
Karimi M; Mohammadi H; Hemmatzadeh M; Mohammadi A; Rafatpanah H; Baradaran B
Biomed Pharmacother; 2017 Jan; 85():334-347. PubMed ID: 27887847
[TBL] [Abstract][Full Text] [Related]
20. HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ.
Giam CZ; Semmes OJ
Viruses; 2016 Jun; 8(6):. PubMed ID: 27322308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
